Immunological challenges for peptide-based immunotherapy in glioblastoma

Cancer Treatment Reviews

Volumn 40, Issue 2, 2014, Pages 248-258

  Mohme, Malte ^a,b   Neidert, Marian C ^a   Regli, Luca ^a   Weller, Michael ^c   Martin, Roland ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Anti tumor response; Glioblastoma; Glioma; Immunotherapy; Peptide vaccination; Tumor immunology

Indexed keywords

BASILIXIMAB; BEVACIZUMAB; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; FREUND ADJUVANT; IMA950 VACCINE; INTERLEUKIN 10; INTERLEUKIN 2; LYMPHOTOXIN; MITUMPROTIMUT T; PEPTIDE VACCINE; PROSTAGLANDIN E2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RINDOPEPIMUT; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITESPEN;

ADJUVANT THERAPY; ANGIOGENESIS; APOPTOSIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CD8+ T LYMPHOCYTE; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MULTIMODALITY CANCER THERAPY; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TUMOR ESCAPE;

ANTI-TUMOR RESPONSE; GLIOBLASTOMA; GLIOMA; IMMUNOTHERAPY; PEPTIDE-VACCINATION; TUMOR IMMUNOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; PEPTIDES;

EID: 84888300327     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.08.008     Document Type: Review

References (123)

1. Preusser M., de Ribaupierre S., Wohrer A., Erridge S.C., Hegi M., Weller M., et al. Current concepts and management of glioblastoma. Ann Neurol 2011, 70:9-21.
2. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
3. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
4. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64:479-489.
5. Weller M., Stupp R., Reifenberger G., Brandes A.A., van den Bent M.J., Wick W., et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol 2010, 6:39-51.
6. Curran W.J., Scott C.B., Horton J., Nelson J.S., Weinstein A.S., Fischbach A.J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993, 85:704-710.
7. Choucair A.K., Levin V.A., Gutin P.H., Davis R.L., Silver P., Edwards M.S., et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 1986, 65:654-658.
8. Pilkington G.J., Bjerkvig R., De Ridder L., Kaaijk P. In vitro and in vivo models for the study of brain tumour invasion. Anticancer Res 1997, 17:4107-4109.
9. Giese A., Kluwe L., Laube B., Meissner H., Berens M.E., Westphal M. Migration of human glioma cells on myelin. Neurosurgery 1996, 38:755-764.
10. Pichlmeier U., Bink A., Schackert G., Stummer W. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 2008, 10:1025-1034.
11. Squatrito M., Holland E.C. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res 2011, 71:5945-5949.
12. Beier D., Schulz J.B., Beier C.P. Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer 2011, 10:128.
13. Bonavia R., Inda M.M., Cavenee W.K., Furnari F.B. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011, 71:4055-4060.
14. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011, 29:235-271.
15. Beckman R.A., Loeb L.A. Genetic instability in cancer: theory and experiment. Semin Cancer Biol 2005, 15:423-435.
16. Vauleon E., Avril T., Collet B., Mosser J., Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010, 2010.
17. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013, 31:51-72.
18. Fooksman D.R., Vardhana S., Vasiliver-Shamis G., Liese J., Blair D.A., Waite J., et al. Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol 2010, 28:79-105.
19. Guermonprez P., Valladeau J., Zitvogel L., Thery C., Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002, 20:621-667.
20. Joffre O.P., Segura E., Savina A., Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol 2012, 12:557-569.
21. Yamanaka R., Itoh K. Peptide-based immunotherapeutic approaches to glioma: a review. Expert Opin Biol Ther 2007, 7:645-649.
22. Kronik N., Kogan Y., Elishmereni M., Halevi-Tobias K., Vuk-Pavlovic S., Agur Z. Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models. PLoS One 2010, 5:e15482.
23. Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7:790-802.
24. Ludewig B., Ochsenbein A.F., Odermatt B., Paulin D., Hengartner H., Zinkernagel R.M. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000, 191:795-804.
25. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
26. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004, 10:909-915.
27. Albesiano E., Han J.E., Lim M. Mechanisms of local immunoresistance in glioma. Neurosurg Clin N Am 2010, 21:17-29.
28. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364:2119-2127.
29. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012.
30. Choi B.D., Archer G.E., Mitchell D.A., Heimberger A.B., McLendon R.E., Bigner D.D., et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009, 19:713-723.
31. Hegi M.E., Rajakannu P., Weller M. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr Opin Neurol 2012, 25:774-779.
32. Ekstrand A.J., James C.D., Cavenee W.K., Seliger B., Pettersson R.F., Collins V.P. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991, 51:2164-2172.
33. Gan H.K., Kaye A.H., Luwor R.B. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009, 16:748-754.
34. Sampson J.H., Archer G.E., Mitchell D.A., Heimberger A.B., Herndon J.E., Lally-Goss D., et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009, 8:2773-2779.
35. Sampson J.H., Heimberger A.B., Archer G.E., Aldape K.D., Friedman A.H., Friedman H.S., et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010, 28:4722-4729.
36. Dutoit V., Herold-Mende C., Hilf N., Schoor O., Beckhove P., Bucher J., et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012, 135:1042-1054.
37. Ebben J.D., Rocque B.G., Kuo J.S. Tumour vaccine approaches for CNS malignancies: progress to date. Drugs 2009, 69:241-249.
38. Lohr J., Ratliff T., Huppertz A., Ge Y., Dictus C., Ahmadi R., et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res 2011, 17:4296-4308.
39. Yang I., Tihan T., Han S.J., Wrensch M.R., Wiencke J., Sughrue M.E., et al. CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci 2010, 17:1381-1385.
40. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
41. Dunn G.P., Fecci P.E., Curry W.T. Cancer immunoediting in malignant glioma. Neurosurgery 2012, 71:201-222. discussion 22-3.
42. Wainwright D.A., Balyasnikova I.V., Chang A.L., Ahmed A.U., Moon K.S., Auffinger B., et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 2012, 18:6110-6121.
43. Waziri A., Killory B., Ogden A.T., Canoll P., Anderson R.C., Kent S.C., et al. Preferential in situ CD4+CD56+ T cell activation and expansion within human glioblastoma. J Immunol 2008, 180:7673-7680.
44. Crane C.A., Ahn B.J., Han S.J., Parsa A.T. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol. 2012, 14:584-595.
45. Kim Y.H., Jung T.Y., Jung S., Jang W.Y., Moon K.S., Kim I.Y., et al. Tumour-infiltrating T-cell subpopulations in glioblastomas. Br J Neurosurg 2012, 26:21-27.
46. Roszman T.L., Brooks W.H. Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin Exp Immunol 1980, 39:395-402.
47. Roth P., Silginer M., Goodman S.L., Hasenbach K., Thies S., Maurer G., et al. Integrin control of the transforming growth factor-beta pathway in glioblastoma. Brain 2013, 136:564-576.
48. Seoane J. TGFbeta and cancer initiating cells. Cell Cycle 2009, 8:3787-3788.
49. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 1997, 20:165-177.
50. Baxevanis C.N., Reclos G.J., Gritzapis A.D., Dedousis G.V., Missitzis I., Papamichail M. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 1993, 72:491-501.
51. Zuber P., Kuppner M.C., De Tribolet N. Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 1988, 18:1623-1626.
52. Liu V.C., Wong L.Y., Jang T., Shah A.H., Park I., Yang X., et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007, 178:2883-2892.
53. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
54. El Andaloussi A., Lesniak M.S. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006, 8:234-243.
55. Heimberger A.B., Abou-Ghazal M., Reina-Ortiz C., Yang D.S., Sun W., Qiao W., et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008, 14:5166-5172.
56. Sonabend A.M., Rolle C.E., Lesniak M.S. The role of regulatory T cells in malignant glioma. Anticancer Res 2008, 28:1143-1150.
57. Elliott L.H., Brooks W.H., Roszman T.L. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J Immunol 1984, 132:1208-1215.
58. Grauer O.M., Nierkens S., Bennink E., Toonen L.W., Boon L., Wesseling P., et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007, 121:95-105.
59. Fecci P.E., Mitchell D.A., Whitesides J.F., Xie W., Friedman A.H., Archer G.E., et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006, 66:3294-3302.
60. Facoetti A., Nano R., Zelini P., Morbini P., Benericetti E., Ceroni M., et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 2005, 11:8304-8311.
61. Yeung J.T., Hamilton R.L., Ohnishi K., Ikeura M., Potter D.M., Nikiforova M.N., et al. LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma. Clin Cancer Res 2013, 19:1816-1826.
62. Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J., Yannelli J.R., Rosenberg S.A. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996, 88:100-108.
63. Zagzag D., Salnikow K., Chiriboga L., Yee H., Lan L., Ali M.A., et al. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 2005, 85:328-341.
64. Lanier L.L. NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
65. Dougan M., Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009, 27:83-117.
66. Wiendl H., Mitsdoerffer M., Hofmeister V., Wischhusen J., Bornemann A., Meyermann R., et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002, 168:4772-4780.
67. Wischhusen J., Friese M.A., Mittelbronn M., Meyermann R., Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol 2005, 64:523-528.
68. Mittelbronn M., Simon P., Loffler C., Capper D., Bunz B., Harter P., et al. Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. J Neuroimmunol 2007, 189:50-58.
69. Wolpert F., Roth P., Lamszus K., Tabatabai G., Weller M., Eisele G. HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. J Neuroimmunol 2012, 250:27-34.
70. Friese M.A., Platten M., Lutz S.Z., Naumann U., Aulwurm S., Bischof F., et al. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 2003, 63:8996-9006.
71. Gomez G.G., Kruse C.A. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 2006, 10:133-146.
72. Schiltz P.M., Gomez G.G., Read S.B., Kulprathipanja N.V., Kruse C.A. Effects of IFN-gamma and interleukin-1beta on major histocompatibility complex antigen and intercellular adhesion molecule-1 expression by 9L gliosarcoma: relevance to its cytolysis by alloreactive cytotoxic T lymphocytes. J Interferon Cytokine Res 2002, 22:1209-1216.
73. Fiore E., Fusco C., Romero P., Stamenkovic I. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 2002, 21:5213-5223.
74. Hemesath T.J., Marton L.S., Stefansson K. Inhibition of T cell activation by the extracellular matrix protein tenascin. J Immunol 1994, 152:5199-5207.
75. Parekh K., Ramachandran S., Cooper J., Bigner D., Patterson A., Mohanakumar T. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer 2005, 47:17-29.
76. Dick S.J., Macchi B., Papazoglou S., Oldfield E.H., Kornblith P.L., Smith B.H., et al. Lymphoid cell-glioma cell interaction enhances cell coat production by human gliomas: novel suppressor mechanism. Science 1983, 220:739-742.
77. Rubinstein N., Alvarez M., Zwirner N.W., Toscano M.A., Ilarregui J.M., Bravo A., et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004, 5:241-251.
78. Badie B., Schartner J., Prabakaran S., Paul J., Vorpahl J. Expression of Fas ligand by microglia: possible role in glioma immune evasion. J Neuroimmunol 2001, 120:19-24.
79. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004, 10:48-54.
80. Miyazaki T., Moritake K., Yamada K., Hara N., Osago H., Shibata T., et al. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation. J Neurosurg 2009, 111:230-237.
81. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9:1269-1274.
82. Platten M., Wick W., Van den Eynde B.J. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 2012, 72:5435-5440.
83. Smith-Garvin J.E., Koretzky G.A., Jordan M.S. T cell activation. Annu Rev Immunol 2009, 27:591-619.
84. Rammensee H.G., Falk K., Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993, 11:213-244.
85. Stevanovic S., Schild H. Quantitative aspects of T cell activation-peptide generation and editing by MHC class I molecules. Semin Immunol 1999, 11:375-384.
86. Yewdell J.W., Haeryfar S.M. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Annu Rev Immunol 2005, 23:651-682.
87. Marrack P., Rubtsova K., Scott-Browne J., Kappler J.W. T cell receptor specificity for major histocompatibility complex proteins. Curr Opin Immunol 2008, 20:203-207.
88. Rammensee H.G., Falk K., Rotzschke O. MHC molecules as peptide receptors. Curr Opin Immunol 1993, 5:35-44.
89. *0231. Hum Immunol 2000, 61:334-340.
90. Rammensee H.G., Weinschenk T., Gouttefangeas C., Stevanovic S. Towards patient-specific tumor antigen selection for vaccination. Immunol Rev 2002, 188:164-176.
91. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
92. Byrne K.T., Turk M.J. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget 2011, 2:684-694.
93. Rosenberg S.A., White D.E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996, 19:81-84.
94. Romero P., Cerottini J.C., Speiser D.E. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother 2004, 53:249-255.
95. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
96. Lamszus K., Gunther H.S. Glioma stem cells as a target for treatment. Target Oncol 2010, 5:211-215.
97. Falk K., Rotzschke O., Stevanovic S., Jung G., Rammensee H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991, 351:290-296.
98. Singh-Jasuja H., Emmerich N.P., Rammensee H.G. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother 2004, 53:187-195.
99. Weinzierl A.O., Lemmel C., Schoor O., Muller M., Kruger T., Wernet D., et al. Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics: MCP 2007, 6:102-113.
100. Neidert M.C., Schoor O., Trautwein C., Trautwein N., Christ L., Melms A., et al. Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy. J Neurooncol 2013, 111:285-294.
101. Kennedy R., Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008, 222:129-144.
102. Zajac A.J., Murali-Krishna K., Blattman J.N., Ahmed R. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Curr Opin Immunol 1998, 10:444-449.
103. Kennedy R., Celis E. T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol 2006, 177:2862-2872.
104. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003, 421:852-856.
105. Assudani D., Cho H.I., DeVito N., Bradley N., Celis E. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res 2008, 68:9892-9899.
106. Newcomb E.W., Demaria S., Lukyanov Y., Shao Y., Schnee T., Kawashima N., et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res 2006, 12:4730-4737.
107. Glass R., Synowitz M., Kronenberg G., Walzlein J.H., Markovic D.S., Wang L.P., et al. Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J Neurosci 2005, 25:2637-2646.
108. Accolla R.S., Tosi G. Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines. J Transl Med 2012, 10:154.
109. Ochiai H., Archer G.E., Herndon J.E., Kuan C.T., Mitchell D.A., Bigner D.D., et al. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunol Immunother 2008, 57:115-121.
110. Melief C.J., van der Burg S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008, 8:351-360.
111. Purcell A.W., McCluskey J., Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007, 6:404-414.
112. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999, 59:3128-3133.
113. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010, 127:759-767.
114. Nizard P., Gross D.A., Babon A., Chenal A., Beaumelle B., Kosmatopoulos K., et al. Anchoring cytokines to tumor cells for the preparation of anticancer vaccines without gene transfection in mice. J Immunother 2003, 26:63-71.
115. Pellegatta S., Poliani P.L., Stucchi E., Corno D., Colombo C.A., Orzan F., et al. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro Oncol 2010, 12:377-388.
116. Brem H., Gabikian P. Biodegradable polymer implants to treat brain tumors. J Controlled Release 2001, 74:63-67.
117. Bogdahn U., Hau P., Stockhammer G., Venkataramana N.K., Mahapatra A.K., Suri A., et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011, 13:132-142.
118. Rodon J, Sepúlveda JM, Azaro A, Calvo E, Seoane J, Brana et al. Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor, LY2157299 monohydrate (LY). ASCO Annual Meeting 2013.
119. Wang N.X., Bazdar D.A., Sieg S.F., von Recum H.A. Microparticle delivery of Interleukin-7 to boost T-cell proliferation and survival. Biotechnol Bioeng 2012, 109:1835-1843.
120. Warger T., Schild H., Rechtsteiner G. Initiation of adaptive immune responses by transcutaneous immunization. Immunol Lett 2007, 109:13-20.
121. Pan J., Jin P., Yan J., Kabelitz D. Anti-angiogenic active immunotherapy: a new approach to cancer treatment. Cancer Immunol Immunother 2008, 57:1105-1114.
122. Hou J., Tian L., Wei Y. Cancer immunotherapy of targeting angiogenesis. Cell Mol Immunol 2004, 1:161-166.
123. Liu G., Akasaki Y., Khong H.T., Wheeler C.J., Das A., Black K.L., et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene 2005, 24:5226-5234.